ARTICLE | Company News
Highmark, AstraZeneca in outcomes-based Symbicort contract
April 20, 2018 4:33 PM UTC
Blue Cross Blue Shield's Highmark Inc. affiliate and AstraZeneca plc (LSE:AZN; NYSE:AZN) entered into an outcomes-based contract for Symbicort budesonide/formoterol to treat symptoms in chronic obstructive pulmonary disease (COPD) and asthma patients in Pennsylvania, West Virginia and Delaware.
A Highmark spokesperson told BioCentury that the agreement is the company's first outcomes-based contract for a respiratory therapy...